Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

382

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

BIOLOGICAL: QGE031
BIOLOGICAL: Omalizumab
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals